{"id":61108,"title":"FDA review documents trigger sell-off in Revolution Medicines shares","publisher":"Stockmark.IT","author":"Stockmark.IT Website","published":"2026-10-10T09:03:43+00:00","modified":"2026-10-10T09:03:43+00:00","canonical_url":"https://stockmark.it/fda-review-docs-spark-revolution-sell-off-zealand-diabetes-data-underw/","markdown_url":"https://stockmark.it/fda-review-docs-spark-revolution-sell-off-zealand-diabetes-data-underw.md","json_url":"https://stockmark.it/fda-review-docs-spark-revolution-sell-off-zealand-diabetes-data-underw.json","category":"Companies","categories":["Companies","Drug Research"],"featured_image":"https://i0.wp.com/stockmark.it/wp-content/uploads/2026/10/fda-review-documents-trigger-sell-off-in-revolution.png?fit=1536%2C1024&quality=80&ssl=1","format":"news","language":"en-GB","content":"Shares of Revolution Medicines declined by six per cent on Thursday after the release of review documents from the Food and Drug Administration. The newly disclosed information suggests that the company’s pancreatic cancer drug, Rasonque, may not be as broadly effective as previously anticipated. Specifically, the documents indicate that the medication might be less effective in certain patient groups for which it is approved. This development has prompted a significant reassessment of the drug’s clinical profile by investors and market analysts.\n\nRasonque received FDA approval in August based on data demonstrating that it nearly doubled survival rates compared to chemotherapy in patients who had already progressed on chemotherapy treatments. However, the recent FDA documents reveal a more nuanced picture regarding tumour responses. The data show that tumour responses were markedly better than chemotherapy in trial enrollees with a specific KRAS mutation known as G12V. In contrast, the difference was more modest among patients with a G12D mutation, which represents the largest share of pancreatic cancer patients. Furthermore, the results were worse in individuals with a G12R mutation. This stratification of efficacy has raised concerns about the drug’s overall utility across the broader patient population.\n\nIn response to the share price drop, many Wall Street analysts moved to defend the company’s position. In client notes, several analysts argued that the sell-off was overdone, misguided, or an investor overreaction. However, not all views were uniformly supportive. Andrew Berens, an analyst at Leerink Partners, referred to the disclosure as a crack in the armour for Rasonque. He viewed the situation as an opportunity for competitors who possess G12D-specific inhibitors or next-generation medicines. The mixed reaction from the financial community highlights the ongoing debate regarding the long-term competitive positioning of Revolution Medicines’ flagship product.\n\nElsewhere in the biopharmaceutical sector, Zealand Pharma reported that its experimental drug petrelintide, developed in partnership with Roche, helped people with obesity and diabetes lose up to nine per cent of their body weight over 28 weeks in a Phase 2 trial. This represented a seven percentage point improvement over those who received a placebo. The therapy was also associated with clinically relevant blood sugar reductions, which were between 0.6 and 0.9 percentage points better than the placebo group. Analysts noted that the weight loss numbers were comparable to an Eli Lilly drug, which is also an amylin analog and a potential alternative to GLP-1 medicines. While the therapy’s seemingly benign safety profile was applauded, the effects on blood sugar were viewed as less impressive. William Blair analyst Andy Hsieh predicted that the drug will likely be used primarily in the maintenance setting.\n\nPfizer’s HER2-targeting breast cancer drug Tukysa has also seen an expansion in its approved use. Previously developed by Seagen, Tukysa first came to market in 2020 as a second-line treatment for HER2-positive breast tumours. The new clearance makes the drug available in the frontline setting, where it will be prescribed as part of a chemotherapy-free maintenance regimen involving the targeted medications Herceptin and Perjeta. In a Phase 3 trial, this regimen was associated with a 36 per cent reduction in the risk of disease progression or death when compared to Herceptin and Perjeta alone.\n\nUltragenyx has secured $210 million by selling one of two regulatory fast passes it was recently awarded by the FDA. The priority voucher sold on Wednesday was related to the clearance of Glenglycos, a gene therapy for a rare glycogen storage disease. The company received another voucher upon the approval of the Sanfilippo gene therapy Fayuvi. Lachlan Hanbury-Brown, an analyst at William Blair, described the sale as an incrementally positive development that will significantly strengthen the company’s balance sheet. This financial move follows the company’s statement last month that it would consider cost cuts after the failure of a key experimental treatment for Angelman syndrome.\n\nFinally, biotech investment firm TCGX announced that it has closed a $600 million fund to support biotechnology companies in Asia. Known as TCGX Asia Life Sciences Fund I, the investment vehicle will operate separately from, but in close synergy with, two other TCGX funds that back biotechs in the US and Europe. The firm stated that the fund is backed by a diverse group of international institutional investors, though it did not provide specifics. Alongside the fund’s launch, TCGX is opening new offices in Shanghai and Hong Kong."}